| Literature DB >> 26861363 |
Linfu Zhou1,2, Rui Wu3, Xiaodan Shi4, Dongyun Feng5, Guodong Feng6, Yining Yang7, Wen Dai8, Ting Bian9, Tingting Liu10, Ying He11, Ming Shi12, Gang Zhao13.
Abstract
Early diagnosis and treatment are crucial for the outcome of central nervous system (CNS) infections. In this study, we developed a multiplex PCR-Luminex assay for the simultaneous detection of five major pathogens, including Mycobacterium tuberculosis, Cryptococcus neoformans, Streptococcus pneumoniae, and herpes simplex virus types 1 and 2, which frequently cause CNS infections. Through the hybridization reaction between multiplex PCR-amplified targets and oligonucleotide "anti-TAG" sequences, we found that the PCR-Luminex assay could detect as low as 10¹-10² copies of synthetic pathogen DNAs. Furthermore, 163 cerebrospinal fluid (CSF) specimens from patients with suspected CNS infections were used to evaluate the efficiency of this multiplex PCR-Luminex method. Compared with Ziehl-Neelsen stain, this assay showed a high diagnostic accuracy for tuberculosis meningitis (sensitivity, 90.7% and specificity, 99.1%). For cryptococcal meningitis, the sensitivity and specificity were 92% and 97.1%, respectively, compared with the May Grunwald Giemsa (MGG) stain. For herpes simplex virus types 1 and 2 encephalitis, the sensitivities were 80.8% and 100%, and the specificities were 94.2% and 99%, respectively, compared with Enzyme Linked Immunosorbent Assay (ELISA) assays. Taken together, this multiplex PCR-Luminex assay showed potential efficiency for the simultaneous detection of five pathogens and may be a promising supplement to conventional methods for diagnosing CNS infections.Entities:
Keywords: Luminex technology; central nervous system infections; cerebrospinal fluid; multiplex PCR
Mesh:
Year: 2016 PMID: 26861363 PMCID: PMC4772213 DOI: 10.3390/ijerph13020193
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
The specific primers used in multiplex PCR with Luminex assay.
| Organism | GenBank Accession No. | Target Gene | Oligonucleotide Sequence of Primer (5’–3’) | Length (bp) | Position (5’–3’) |
|---|---|---|---|---|---|
| CP009480.1 | IS986 | F-
| 245 | 889650–889894 | |
| L38588.1 | URA | F-
| 360 | 390–749 | |
|
| AF467249.1 | lytA | F-
| 124 | 328–451 |
|
| X14112.1 | Gene 42 | F-
| 257 | 93557–93813 |
|
| Z86099.2 | TK | F-
| 234 | 46635–46868 |
F = forward, R = reverse. Unique 24 base oligonucleotide “TAG” sequences and 12-carbon amine containing group are indicated by underline and bold, respectively. R-primers were biotinylated at 5’ terminus. HSV-1 and HSV-2, herpes simplex virus types 1 and 2.
Figure 1Agarose gel electrophoresis showed the results of five-plex PCR amplification followed by M. tuberculosis, HSV-1, HSV-2, C. neoformans and S. pneumoniae plasmid DNAs, respectively. Each plasmid DNAs was successfully amplified by five-plex PCR Reaction System. Lanes are as follows: M, DNA Marker 2000; 1, M. tuberculosis 245 bp; 2, HSV-1 257 bp; 3, HSV-2 234 bp; 4, C. neoformans 360 bp; 5, negative control; 6, S. pneumoniae 124 bp.
Figure 2Detection of target products by the five-plex PCR-Luminex showed a high specificitity. Distilled water was used as the negative control (NC). Each bar represents the average MFI of triplicate samples. The error bars indicate standard deviations. TB, M. tuberculosis; CN, C. neoformans; SPN, S. pneumoniae; HSV-1 and HSV-2, herpes simplex virus types 1 and 2.
Analytical sensitivity of serial dilution plasmid.
| Organism | Plasmid Quantity (Copies) | cMFI |
|---|---|---|
| 108 | 16.95 ± 0.45 | |
| 106 | 10.06 ± 0.22 | |
| 104 | 7.49 ± 0.30 | |
| 102 | 6.79 ± 0.20 | |
| 101 | 0.93 ± 0.07 | |
| HSV-1 | 102 | 11.41 ± 0.72 |
| 50 | 6.56 ± 0.20 | |
| 10 | 5.30 ± 0.31 | |
| 5 | 2.30 ± 0.12 | |
| 1 | 2.45 ± 0.15 | |
| HSV-2 | 108 | 17.72 ± 0.59 |
| 106 | 7.14 ± 0.38 | |
| 104 | 6.19 ± 0.14 | |
| 102 | 3.49 ± 0.07 | |
| 101 | 2.25 ± 0.02 | |
| 108 | 34.80 ± 0.21 | |
| 106 | 31.86 ± 0.18 | |
| 104 | 28.29 ± 0.45 | |
| 102 | 9.62 ± 0.12 | |
| 101 | 1.23 ± 0.10 | |
|
| 108 | 8.78 ± 0.47 |
| 106 | 6.15 ± 0.36 | |
| 104 | 4.94 ± 0.29 | |
| 102 | 3.77 ± 0.22 | |
| 101 | 2.18 ± 0.14 |
Cutoff cMFI = 3.0. All samples were performed in triplicate. If the results from a duplicate sample analysis exceeded the Cutoff cMFI, the sample was defined as PCR-Luminex assay positive.
M. tuberculosis detected by PCR-Luminex assay vs. indirect smear microscopy.
| PCR-Luminex | Smear Positive | Smear Negative | Sensitivity | Specificity | Kappa |
|---|---|---|---|---|---|
| (+) | 49 | 1 | 90.7% | 99.1% | 0.9153 |
| (−) | 5 | 108 |
C. neoformans detected by PCR-Luminex assay vs. MGG stain.
| PCR-Luminex | MGG Positive | MGG Negative | Sensitivity | Specificity | Kappa |
|---|---|---|---|---|---|
| (+) | 23 | 4 | 92% | 97.1% | 0.8628 |
| (−) | 2 | 134 |
MGG, May Grunwald Giemsa stain.
HSV-1 or HSV-2 detected by PCR-Luminex assay vs. ELISA assay.
| PCR-Luminex | ELISA Positive | ELISA Negative | Sensitivity | Specificity | Kappa | |
|---|---|---|---|---|---|---|
| HSV-1 | (+) | 21 | 8 | 80.8% | 94.2% | 0.7158 |
| (−) | 5 | 129 | ||||
| HSV-2 | (+) | 1 | 1 | 100% | 99% | 0.6639 |
| (−) | 0 | 161 | ||||
ELISA, Enzyme linked immunosorbent assay.